Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2017

Open Access 01-12-2017 | Research article

Comparison of demographic characteristics and psychiatric comorbidity among methamphetamine-, heroin- and methamphetamine-heroin co- dependent males in Hunan, China

Authors: Huixi Dong, Mei Yang, Liang Liu, Chenxi Zhang, Mengqi Liu, Yidong Shen, Huanzhong Liu, Wei Hao

Published in: BMC Psychiatry | Issue 1/2017

Login to get access

Abstract

Background

There is little research of psychiatric comorbidity differences among people with different types of drug dependence in Chinese population. We explored demographic and comorbid psychiatric differences among methamphetamine- dependent males (MDs), heroin-dependent males (HDs) and methamphetamine and heroin co-dependent males (M/HDs) in Hunan province, China.

Methods

A cross-sectional, structured and clinical interview method was used to examine differences in DSM-IV-TR Axis I Disorders among 346 MDs, 698 HDs and 247 M/HDs from three compulsory rehabilitation centers and two voluntary rehabilitation centers in Hunan.

Results

MDs and M/HDs were younger, more likely to choose inhalation administration, less likely to have a family history of substance use, less likely to have undergone detoxification treatment, had higher incomes and shorter duration of drug use than HDs. Overall, methamphetamine-dependence related to higher rates of current and lifetime psychotic disorders, lifetime hallucinogen use disorders. Heroin-dependence related to higher rates of current and lifetime substance-induced mood disorders, sedative/hypnotic/anxiolytic and other drug use disorders and current alcohol use disorder. For M/HDs, they were more likely to have any other lifetime substance use disorders than MDs and HDs.

Conclusions

There were substantial differences in epidemiological characteristics and comorbidity among MD, HD and M/HD groups, which highlights the urgent need to develop treatment services and policies for drug-specific users in China.
Appendix
Available only for authorised users
Literature
1.
Aggarwal M, Banerjee A, Singh SM, Mattoo SK, Basu D. Substance-induced psychotic disorders: 13-year data from a de-addiction centre and their clinical implications. Asian J Psychiatr. 2012;5(3):220–4.CrossRefPubMed
2.
Aharonovich E, Liu X, Nunes E, Hasin DS. Suicide attempts in substance abusers: effects of major depression in relation to substance use disorders. Am J Psychiatry. 2002;159(9):1600–2.CrossRefPubMed
3.
Annual Report on Drug Control in China. National Narcotic Control Commission (NNCC). Beijing: Ministry of Public Security; 2004.
4.
Annual Report on Drug Control in China. National Narcotic Control Commission (NNCC). Beijing: Ministry of Public Security; 2016.
5.
Barati M, Ahmadpanah M, Soltanian AR. Prevalence and factors associated with methamphetamine use among adult substance abusers. J Res Health Sci. 2014;14(3):221–6.PubMed
6.
Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Loberg EM, Medhus S, Tanum L, Franck J. Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry. 2012;12:221.CrossRefPubMedPubMedCentral
7.
Center for Substance Abuse Treatment. Substance Abuse treatment for persons with co-occurring disorders. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2005. (Treatment Improvement Protocol (TIP) Series, No. 42.) 9 Substance-Induced Disorders. Available from: https://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK64178/​
8.
Chen CK, Lin SK, Sham PC, Ball D, Loh EW, Hsiao CC, Chiang YL, Ree SC, Lee CH, Murray RM. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol Med. 2003;33(8):1407–14.CrossRefPubMed
9.
Compton WR, Cottler LB, Jacobs JL, Ben-Abdallah A, Spitznagel EL. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry. 2003;160(5):890–5.CrossRefPubMed
10.
Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry. 2006;67(2):247–57.CrossRefPubMed
11.
Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM, White WR, Perez-Reyes M. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos. 1993;21(4):717–23.PubMed
12.
Curran GM, Sullivan G, Williams K, Han X, Collins K, Keys J, Kotrla KJ. Emergency department use of persons with comorbid psychiatric and substance abuse disorders. Ann Emerg Med. 2003;41(5):659–67.CrossRefPubMed
13.
Evans EA, Grella CE, Washington DL, Upchurch DM. Gender and race/ethnic differences in the persistence of alcohol, drug, and poly-substance use disorders. Drug Alcohol Depend. 2017;174:128–36.CrossRefPubMed
14.
Fang YX, Wang YB, Shi J, Liu ZM, Lu L. Recent trends in drug abuse in China. Acta Pharmacol Sin. 2006;27(2):140–4.CrossRefPubMed
15.
Farnia V, Shakeri J, Tatari F, Juibari TA, Bajoghli H, Golshani S, et al. Demographic and mental history-related data predicted occurrence of psychosis in metamphetamine users. Psychiatry Res. 2016;240:431–4.CrossRefPubMed
16.
First M, Spitzer R, Gibbon M, Williams J. Structured clinical interview for DSM-IV-TR Axis I disorders. New York: Biometrics Research Department, New York State Psychiatric Institute; 2002.
17.
Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R. Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abus Treat. 2008;35(4):445–50.CrossRef
18.
Goldstein RB, Dawson DA, Chou SP, Grant BF. Sex differences in prevalence and comorbidity of alcohol and drug use disorders: results from wave 2 of the National Epidemiologic Survey on alcohol and related conditions. J Stud Alcohol Drugs. 2012;73(6):938–50.CrossRefPubMedPubMedCentral
19.
Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, Carlo G, Bevins RA. Methamphetamine-associated psychosis. J NeuroImmune Pharmacol. 2012;7(1):113–39.CrossRefPubMed
20.
Grella CE, Karno MP, Warda US, Niv N, Moore AA. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav. 2009;34(6–7):498–504.CrossRefPubMedPubMedCentral
21.
Hser YI, Evans E, Huang D, Brecht ML, Li L. Comparing the dynamic course of heroin, cocaine, and methamphetamine use over 10 years. Addict Behav. 2008;33(12):1581–9.CrossRefPubMedPubMedCentral
22.
Ikeda M, Okahisa Y, Aleksic B, Won M, Kondo N, Naruse N, Aoyama-Uehara K, Sora I, Iyo M, Hashimoto R, Kawamura Y, Nishida N, Miyagawa T, Takeda M, Sasaki T, Tokunaga K, Ozaki N, Ujike H, Iwata N. Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia. Neuropsychopharmacology. 2013;38(10):1864–70.CrossRefPubMedPubMedCentral
23.
Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol. 2010;69(6):578–92.CrossRefPubMedPubMedCentral
24.
Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, Thummawomg P, Dumrongchai U, Chutha W. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev. 2010;29(4):456–61.CrossRefPubMed
25.
Landheim AS, Bakken K, Vaglum P. Impact of comorbid psychiatric disorders on the outcome of substance abusers: a six year prospective follow-up in two Norwegian counties. BMC Psychiatry. 2006;6(1):1–11.CrossRef
26.
Larney S, Gowing L, Mattick RP, Farrell M, Hall W, Degenhardt L. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug Alcohol Rev. 2014;33(2):115–28.CrossRefPubMed
27.
Leamon MH, Flower K, Salo RE, Nordahl TE, Kranzler HR, Galloway GP. Methamphetamine and paranoia: the methamphetamine experience questionnaire. Am J Addict. 2010;19(2):155–68.CrossRefPubMedPubMedCentral
28.
Lecomte T, Mueser KT, MacEwan W, Thornton AE, Buchanan T, Bouchard V, et al. Predictors of persistent psychotic symptoms in persons with methamphetamine abuse receiving psychiatric treatment. J Nerv Ment Dis. 2013;201(12):1085–9.CrossRefPubMed
29.
Leri F, Bruneau J, Stewart J. Understanding polydrug use: review of heroin and cocaine co-use. Addiction. 2003;98(1):7–22.CrossRefPubMed
30.
Li L, Assanangkornchai S, Duo L, McNeil E, Li J. Cross-border activities and association with current methamphetamine use among Chinese injection drug users (IDUs) in a China-Myanmar border region. Drug Alcohol Depend. 2014;138(5):48–53.CrossRefPubMed
31.
McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006;101(10):1473–8.CrossRefPubMed
32.
McKetin R, Ross J, Kelly E, Baker A, Lee N, Lubman DI, Mattick R. Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants. Drug Alcohol Rev. 2008;27(3):277–85.CrossRefPubMed
33.
Mezzich JE, Kirmayer LJ, Kleinman A, et al. The place of culture in DSM-IV. J Nerv Ment Dis. 1999;187(8):457–64.CrossRefPubMed
34.
Mitcheson M, Hawks D, Malone S, Davidson J, Hitchens L. Sedative abuse by heroin addicts. Lancet. 1970;1(7647):606–7.CrossRefPubMed
35.
Najt P, Fusar-Poli P, Brambilla P. Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiatry Res. 2011;186(2–3):159–64.CrossRefPubMed
36.
Novak SP, Kral AH. Comparing injection and non-injection routes of administration for heroin, methamphetamine, and cocaine users in the United States. J Addict Dis. 2011;30(3):248–57.CrossRefPubMedPubMedCentral
37.
Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence. JAMA. 2004;291:1887–96.CrossRefPubMed
38.
Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry. 2004;56(10):793–802.CrossRefPubMed
39.
Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369(9566):1047–53.CrossRefPubMed
40.
Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, Li X, Zhang Y, Wang Z. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. 2009;373(9680):2041–53.CrossRefPubMed
41.
Samet S, Fenton MC, Nunes E, Greenstein E, Aharonovich E, Hasin D. Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. Addiction. 2013;108(1):115–23.CrossRefPubMed
42.
Schuckit MA. Drug and alcohol Abuse: a clinical guide to diagnosis and treatment. 6th ed. New York: Springer; 2006a.
43.
Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011;186(2–3):356–61.CrossRefPubMed
44.
Schuckit MA. Comorbidity between substance use disorders and psychiatric conditions. Addiction. 2006b;101(supplement):76–88.CrossRefPubMed
45.
46.
Tate SR, Brown SA, Unrod M, Ramo DE. Context of relapse for substance-dependent adults with and without comorbid psychiatric disorders. Addic Behav. 2004;29(9):1707–24.CrossRef
47.
48.
Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci. 2004;1025(1):279–87.CrossRefPubMed
49.
Yen CF, Chong MY. Comorbid psychiatric disorders, sex, and methamphetamine use in adolescents: a case-control study. Compr Psychiatry. 2006;47(3):215–20.CrossRefPubMed
Metadata
Title
Comparison of demographic characteristics and psychiatric comorbidity among methamphetamine-, heroin- and methamphetamine-heroin co- dependent males in Hunan, China
Authors
Huixi Dong
Mei Yang
Liang Liu
Chenxi Zhang
Mengqi Liu
Yidong Shen
Huanzhong Liu
Wei Hao
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2017
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-017-1346-7

Other articles of this Issue 1/2017

BMC Psychiatry 1/2017 Go to the issue

Research article

Depression stigma and migration – results of a survey from Germany

Research article

Study approach and field work procedures of the MentDis_ICF65+ project on the prevalence of mental disorders in the older adult European population

Research article

Barriers and facilitators in accessing dementia care by ethnic minority groups: a meta-synthesis of qualitative studies

Research article

Early response in cognitive-behavior therapy for syndromes of medically unexplained symptoms

Research article

Examining differences in cognitive and affective theory of mind between persons with high and low extent of somatic symptoms: an experimental study

Research article

Changes in event-related potentials in patients with first-episode schizophrenia and their siblings